For many years, the main guidelines have been recommending the use of betablocker therapy in patients after myocardial infarction (MI) [1,2]. This recommendation entails a high class and grade for patients with reduced left ventricular function while for those with preserved or moderately reduced ejection fraction (EF), the recommendation is less stringent. A series of evidence, in the last decade, has questioned the efficacy of betablockers in the post-MI period, starting from the meta-analysis of Bangalore et al.
